Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer

被引:174
作者
Galalae, RM
Martinez, A
Mate, T
Mitchell, C
Edmundson, G
Nuernberg, N
Eulau, S
Gustafson, G
Gribble, M
Kovács, G
机构
[1] Univ Hosp Schleswig Holstein, Clin Radiat Therapy, Kiel, Germany
[2] Univ Hosp Schleswig Holstein, Urol Clin, Kiel, Germany
[3] William Beaumont Hosp, Dept Radiat Oncol, Royal Oak, MI USA
[4] William Beaumont Hosp, Dept Urol, Royal Oak, MI 48072 USA
[5] Seattle Prostate Inst, Clin Radiat Therapy, Seattle, WA USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2004年 / 58卷 / 04期
关键词
conformal HDR brachytherapy; prostate cancer; pelvic irradiation; androgen deprivation; risk factors;
D O I
10.1016/j.ijrobp.2003.08.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of this study is to analyze, during the prostate-specific antigen (PSA) era, the long-term outcome of patients treated with conformal high-dose-rate (HDR) brachytherapy boost to the prostate with or without androgen deprivation therapy (ADT) when patients are stratified by risk factors for failure. Methods and Materials: Between 1986 and 2000, 611 patients were treated for clinically localized prostate cancer in three prospective trials of external beam radiation therapy (EBRT) and dose-escalating HDR brachytherapy (BT) boost. There were 104 patients treated at Seattle, 198 at Kiel University, and 309 at William Beaumont Hospital. Of the 611 patients, 177 received a short course of neoadjuvant/concurrent ADT. The patients were divided into three risk groups. Group I, comprised of 46 patients, had stage less than or equal toT2a, Gleason score (GS) less than or equal to6, and initial PSA (iPSA) less than or equal to 10 ng/mL. Group II comprised 188 patients with stage greater than or equal toT2b, GS greater than or equal to 7, and iPSA greater than or equal to 10, with any one factor higher. Group III included 359 patients with any two risk factors higher. The American Society for Therapeutic Radiology and Oncology definition for biochemical failure was used. Results: The mean follow-up was 5 years (range, 0.2-15.3). For the 611 patients, the 5-year and 10-year biochemical control (BC) rates were 77% and 73%, disease-free survival (DFS) was 67% and 49%, and cause-specific survival (CSS) was 96% and 92%, respectively. BC at 5 years for Group I patients was 96%, for Group II 88%, and for Group III patients 69%. CSS at 5 years was 100% in Group I, 99% in Group II, and 95% in Group III patients. In univariate and multiple regression analyses for BC, risk group, stage, iPSA, and GS were significant in predicting failure. However, age, follow-up interval, and ADT did not. Conclusions: EBRT with HDR-BT produced excellent long-term outcomes in terms of BC, DFS, and CSS in patients with prostate cancer even for those at highest risk. Conformal HDR-BT is both a precise dose delivery system and an effective treatment for both favorable and unfavorable prostate cancer. The addition of a short course of neoadjuvant/concurrent ADT failed to improve outcome. The results were similar at all three institutions, giving credence to the reproducibility of the brachytherapy treatment. (C) 2004 Elsevier Inc.
引用
收藏
页码:1048 / 1055
页数:8
相关论文
共 33 条
[1]  
BERTERMANN H, 1990, BRACHYTHERAPY HDR LD, P282
[2]   Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes [J].
Blasko, JC ;
Mate, T ;
Sylvester, JE ;
Grimm, PD ;
Cavanagh, W .
SEMINARS IN RADIATION ONCOLOGY, 2002, 12 (01) :81-94
[3]   The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma [J].
Blasko, JC ;
Grimm, PD ;
Sylsvester, JE ;
Cavanagh, W .
RADIOTHERAPY AND ONCOLOGY, 2000, 57 (03) :273-278
[4]   Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [J].
Bolla, M ;
Gonzalez, D ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Gil, T ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) :295-300
[5]  
Brenner DJ, 2002, INT J RADIAT ONCOL, V52, P6
[6]  
Chassagne D., 1997, Dose and Volume Specification for Reporting Interstitial Therapy
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]  
Fair WR, 2000, MOL UROL, V4, P241
[9]   Is α/β for prostate tumors really low? [J].
Fowler, J ;
Chappell, R ;
Ritter, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (04) :1021-1031
[10]   Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer [J].
Galalae, RM ;
Kovács, G ;
Schultze, J ;
Loch, T ;
Rzehak, P ;
Wilhelm, R ;
Bertermann, H ;
Buschbeck, B ;
Kohr, P ;
Kimmig, B .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (01) :81-90